SASanjar Alam

Sanjar Alam

*This is an algorithmically generated author record based on publicly available information.

Sanjar Alam has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Anand K. Bhandari

    Department of Pharmaceutics, Shivalik College of Pharmacy Nangal 140126 India

    1 shared publication
  • Anju Jangra

    Department of Pharmaceutics, Shivalik College of Pharmacy Nangal 140126 India

    1 shared publication
  • Ashu Mittal

    Department of Pharmaceutics, KIET School of Pharmacy, KIET Group of Institutions, 13 KM stone, NH-58, Ghaziabad-Meerut Road, Ghaziabad, Uttar Pradesh IN 201206, India

    1 shared publication
  • Ashutosh Badola

    Department of Pharmaceutics, Shivalik College of Pharmacy Nangal 140126 India

    1 shared publication
  • Ashutosh Bandola

    Department of Pharmaceutics, Shivalik College of Pharmacy Nangal 140126 India

    1 shared publication
  • Ashvini S. Kadam

    Department of Pharmaceutics, Shivalik College of Pharmacy Nangal 140126 India

    1 shared publication

Latest Publications

  • Open Access

    Development of Robust RP-HPLC Method for Posaconazole Assay in Liposomal Formulation using QbD and ICH-Guided Validation with Forced Degradation Analysis

    by Suryadev Sharma, Sanjar Alam, Dheeraj Nagpal

    Posaconazole, an antifungal for invasive infections, requires liposomal formulation to overcome poor solubility and bioavailability, making robust analytical methods essential to ensure quality despite interference from excipients. The aim was to develop and validate a reverse-phase HPLC method for the quantification of posaconazole in a liposomal formulation, utilizing Design Expert software. This method was developed to ensure consistency and reliability as per the ICH guidelines. Chromatographic separation was carried out using a reverse-phase HPLC system assembled with a C18 (ODS) column (150 × 4.6 mm, 3.5 µm). A mixture of methanol and buffer in a 70:30 (v/v) ratio served as the mobile phase, with a flow rate maintained at 1 mL/min. A Quality by design (QbD) approach was employed to optimize key chromatographic conditions, including the ratio of the mobile phases, pH and rate of mobile phase flow. The validation of the developed method was done based on linearity, accuracy, precision, sensitivity, specificity and robustness. The optimized RP-HPLC method showed a linear response with a correlation coefficient (r2) of 0.9994 across the concentration range of 800-1200 µg/mL, ensuring accurate quantification of posaconazole in liposomal formulation. Precision studies demonstrated low relative standard deviations (RSD), with intra-day precision of 0.12% and inter-day precision ranging from 0.36% to 0.39%. The accuracy of the method was 98.4% to 99.4%, confirming its reliability for routine use. Ruggedness testing yielded consistent results from two analysts, with RSD values of 1.38% and 1.42%, indicating the reliability and robustness of the method. Specificity testing confirmed that the method can accurately quantify posaconazole in the presence of formulation excipients, with no interference observed. Furthermore, forced degradation stability studies revealed the stability-indicating ability of the method in terms of a clear distinction between the drug and subsequent degradation products. Based on results, this validated method provides a reliable tool for ensuring the consistent quality and therapeutic efficacy of posaconazole liposomal formulation.


  • Effect of Toll-like Receptor-3 Antagonist on Viral Asthma Exacerbations Via a TLR3/dsRNA Complex Pathway

    by Swamita Arora, Mohit Agrawal, Kantrol Kumar Sahu, Sanjar Alam, Wasim Akram, Mohammad Khalid, Shivendra Kumar, Sunam Saha, Kuldeep Singh, Hema Chaudhary

    Background: The Toll-like receptor-3 (TLR3) ligand Poly(I:C) has been shown to induce a viral aggravation of severe asthma by identifying double-stranded RNA (dsRNA). This study aimed to evaluate the therapeutic role of the TLR3/dsRNA complex inhibitor-calbiochem compound in the treatment of Poly(I:C)-induced viral asthma exacerbations through the ovalbu-min-induced asthma model in Swiss albino mice. Methods: Poly(I:C) and Ovalbumin drugs were injected in mice to sensitize (i.p. on 0, 7, and 14th day) and challenge (i.n. on the 21st and 22nd days). In contrast, the treatment drug TLR3/dsRNA complex inhibitor-calbiochem was given on the 21st and 22nd days intraperitoneally within the study period. In-vivo measurements were carried out in BALF and serum for pro-inflammatory cytokines, inflammatory leukocyte counts, lactate dehydrogenase (LDH) and nitrite levels, lungs/body weight index, and lung tissue histopathology using H and E staining in mice airways. Results: High levels of cytokines (NF-κB, IL-1β, IL-5, RANTES, MIP-2, and MCP-1) are seen in groups exposed to OVA and Poly (I:C). Further, inflammatory leukocyte cell counts, lung-body weight (LW/BW) index, airway hyperresponsiveness (AHR), and lung tissue damage sug-gest exacerbations in mice airways. On the other hand, TLR3/dsRNA complex inhibitor-calbio-chem and dexamethasone significantly reversed these changes toward normal levels. Conclusions: These results suggest that the novel compound TLR3/dsRNA complex inhibitor-calbiochem has a better therapeutic role than dexamethasone for managing inflammatory char-acteristics in asthmatic mice lungs and is a potent target for viral asthma exacerbations

  • Open Access

    TRANSDERMAL DRUG DELIVERY SYSTEM: CURRENT AND FUTURE PROSPECTS OF TDDS

    by Jagdeep Singh Dua, Rihan Raza, Ashu Mittal, Puspendra Kumar, Sanjar Alam, G. K. Surya Prakash, Anju Jangra, Ashvini S. Kadam, Mukesh Ratnaparkhi, Shilpa Chaudhary, et al.